^
    Apply
    PF-07104091 as a Single Agent and in Combination Therapy (NCT04553133)
    Phase 1/2
    Pfizer
    Active, not recruiting
    Last update posted :
    05/16/2024
    Initiation :
    09/16/2020
    Primary completion :
    03/06/2025
    Completion :
    03/06/2025
    HER-2
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • tagtociclib (PF-07104091)